Last reviewed · How we verify
Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]
Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] is a Small molecule drug developed by Medical University of Warsaw. It is currently FDA-approved.
Magnesium Sulphate, marketed by the Medical University of Warsaw, is an injectable solution with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use for critical medical conditions. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] |
|---|---|
| Sponsor | Medical University of Warsaw |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] CI brief — competitive landscape report
- Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] updates RSS · CI watch RSS
- Medical University of Warsaw portfolio CI
Frequently asked questions about Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]
What is Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]?
Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] is a Small molecule drug developed by Medical University of Warsaw.
Who makes Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]?
Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] is developed and marketed by Medical University of Warsaw (see full Medical University of Warsaw pipeline at /company/medical-university-of-warsaw).
What development phase is Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] in?
Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma] is FDA-approved (marketed).